ArunSanyalMD

Gastroenterology • Richmond, VA

Hepatology & Liver Transplantation

Professor, Internal Medicine, Virginia Commonwealth University, Medical College of Virginia School of Medicine

Join to view full profile

Dr. Sanyal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sanyal's full profile

Already have an account?

Office
1250 E Marshall St
Richmond, VA 23298
Phone+1 804-828-6314

Fax+1 804-828-2992

Education & Training

Virginia Commonwealth University Health SystemFellowship, Gastroenterology, 1987 - 1989
Texas Tech University (Amarillo)Residency, Internal Medicine, 1984 - 1987
Maulana Azad Medical CollegeClass of 1981

Certifications & Licensure

VA State Medical License 1986 - 2026
NM State Medical License 1986 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Gastroenterology

Clinical Trials

Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding Start of enrollment: 2006 May 01
Completed
Phase 3
Beta Blockers Versus Variceal Band Ligation and Beta Blockers for Primary Prophylaxis of Variceal Bleeding Start of enrollment: 2006 Dec 01
Terminated
Phase 3
BreathID 13C-Methacetin Breath Test for Detecting Cirrhosis Start of enrollment: 2008 Aug 01
Completed
Phase 3
Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2 Start of enrollment: 2009 Dec 02
Completed
Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia Start of enrollment: 2010 Sep 01
Completed
Prediction of Severity of Liver Disease by a 13C Octanoate Breath Test (OBT) Start of enrollment: 2011 Feb 01
Terminated
Phase 2
Hepatitis B Research Network Adult Cohort Study Start of enrollment: 2010 Dec 01
Completed
Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients Start of enrollment: 2011 Oct 01
Completed
Phase 2
Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis Start of enrollment: 2012 Dec 01
Withdrawn
Phase 2
Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy Start of enrollment: 2013 Apr 03
Terminated
Phase 4
Intestinal Ischemia as a Stimulus for Systemic Inflammatory Response After Cardiac Arrest Start of enrollment: 2013 Sep 01
Completed
Safety and Efficacy of IMM 124-E for Patients With Severe Alcoholic Hepatitis Start of enrollment: 2014 Dec 01
Completed
Phase 2
Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH) Start of enrollment: 2014 Nov 03
Terminated
Phase 2
Alcoholic Hepatitis: A Multicenter, Observational Study by the TREAT Consortium Start of enrollment: 2013 Jun 01
Completed
JKB-121 for the Treatment of Nonalcoholic Steatohepatitis Start of enrollment: 2015 Aug 01
Completed
Phase 2
Great China Fatter Liver Consortium (GC_FLC) Study to Assess the Progress of NAFLD/NASH in Chinese Start of enrollment: 2018 Apr 01
Not yet recruiting
Vitamin C Infusion for TReatment in Sepsis and Alcoholic Hepatitis Start of enrollment: 2019 Apr 16
Completed
Phase 2
A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH. Start of enrollment: 2019 Sep 23
Completed
Phase 2
Non-Invasive Quantification of Liver Health in NASH (N-QUAN) Start of enrollment: 2020 Aug 05
Recruiting
Not Applicable
Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis Start of enrollment: 2020 Jul 10
Completed
Phase 2
Study of the Safety and Tolerability of AXA1665 in Subjects With Mild and Moderate Hepatic Insufficiency Start of enrollment: 2019 Mar 30
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

Ovarian tumor cells gain competitive advantage by actively reducing the cellular fitness of microenvironment cells.
Esha Madan, António M Palma, Vignesh Vudatha, Amit Kumar, Praveen Bhoopathi
Nature Biotechnology. 2024-12-09
Metabolomics at the cutting edge of risk prediction of MASLD.
En Ying Tan, Mark D Muthiah, Arun J Sanyal
Cell Reports. Medicine. 2024-12-05
Semaglutide 2.4 mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial.
Philip N Newsome, Arun J Sanyal, Kristiane A Engebretsen, Iris Kliers, Laura Østergaard
Alimentary Pharmacology & Therapeutics. 2024-12-01

Journal Articles

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19
Gerard J Criner, Onyema Ogbuagu, Kathleen M Mullane, Anuj Gaggar, Diana M Brainard, Arun J Sanyal, Gregory Huhn, JAMA
The Lancet Child & Adolescent Health
Arun Sanyal, Stephen A Harrison, Edgar D Charles, Stephanie Noviello, Manal F Abdelmalek, Eric J Lawitz, Rohit Loomba, The Lancet
HSD17B13 Is a Hepatic Retinol Dehydrogenase Associated with Histological Features of Non‐Alcoholic Fatty Liver Disease
Elizabeth K Speliotes, Arun J Sanyal, Hepatology
Mechanisms of NAFLD Development and Therapeutic Strategies
Arun J Sanyal, Mary Rinella, Scott L Friedman, Nature
Recent Advances in Understanding and Managing Non-Alcoholic Fatty Liver Disease
Somaya Albhaisi, Arun Sanyal, F1000Research
Proton Pump Inhibitor Initiation and Withdrawal Affects Gut Microbiota and Readmission Risk in Cirrhosis
Michael Fuchs, Puneet Puri, Mohammad S Siddiqui, Douglas M Heuman, Jasmohan S Bajaj, Arun J Sanyal, Velimir Luketic, Richard K Sterling, Nature
Join now to see all

Lectures

Evaluation of Acute Kidney Injury in a Cirrhotic Patient: HRS and Beyond
AGC 2018 Annual Scientific Meeting, Philadelphia, PA - 10/8/2018
Future Therapies for NAFLD/NASH
AGC 2018 Annual Scientific Meeting, Philadelphia, PA - 10/8/2018
Advances in the Management of Cirrhosis and Portal Hypertension
AGC 2018 Annual Scientific Meeting, Philadelphia, PA - 10/8/2018

Other

A Novel Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of NAFLD and HCC
Arun Sanyal, MD, Hepatology
https://www.doximity.com/articles/bc75785f-aec8-48b3-bbeb-34d8e6413d27
UpToDate, Wolters Kluwer Health - 2012-11-20
A Novel Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of NAFLD and HCC
Arun Sanyal, MD, Hepatology
https://www.doximity.com/articles/bc75785f-aec8-48b3-bbeb-34d8e6413d27
UpToDate, Wolters Kluwer Health - 2012-09-10
A Novel Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of NAFLD and HCC
Arun Sanyal, MD, Hepatology
https://www.doximity.com/articles/bc75785f-aec8-48b3-bbeb-34d8e6413d27
UpToDate, Wolters Kluwer Health - 2013-04-05
A Novel Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of NAFLD and HCC
Arun Sanyal, MD, Hepatology
https://www.doximity.com/articles/bc75785f-aec8-48b3-bbeb-34d8e6413d27
UpToDate, Wolters Kluwer Health - 2012-06-27
A Novel Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of NAFLD and HCC
Arun Sanyal, MD, Hepatology
https://www.doximity.com/articles/bc75785f-aec8-48b3-bbeb-34d8e6413d27
UpToDate, Wolters Kluwer Health - 2012-12-17
Putting Non-Alcoholic Fatty Liver Disease on the Radar for Primary Care Physicians: How Well Are We Doing?
Arun Sanyal, MD, BioMed Central
https://www.doximity.com/articles/59f5dcf3-ca8b-4736-9f3e-ae9fc8833546
UpToDate, Wolters Kluwer Health - 2012-08-20
Putting Non-Alcoholic Fatty Liver Disease on the Radar for Primary Care Physicians: How Well Are We Doing?
Arun Sanyal, MD, BioMed Central
https://www.doximity.com/articles/59f5dcf3-ca8b-4736-9f3e-ae9fc8833546
UpToDate, Wolters Kluwer Health - 2012-10-18
Putting Non-Alcoholic Fatty Liver Disease on the Radar for Primary Care Physicians: How Well Are We Doing?
Arun Sanyal, MD, BioMed Central
https://www.doximity.com/articles/59f5dcf3-ca8b-4736-9f3e-ae9fc8833546
UpToDate, Wolters Kluwer Health - 2013-04-05
Putting Non-Alcoholic Fatty Liver Disease on the Radar for Primary Care Physicians: How Well Are We Doing?
Arun Sanyal, MD, BioMed Central
https://www.doximity.com/articles/59f5dcf3-ca8b-4736-9f3e-ae9fc8833546
UpToDate, Wolters Kluwer Health - 2013-01-02
Join now to see all

Authored Content

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020

Press Mentions

Genetic Code Deploys Cancer Mafia, New Targeted Drug Gives Them an Offer They Can’t RefuseDecember 10th, 2024
Bridging Clinical Research and Clinical Care with Ai-Aiding Pathologists ToolDecember 9th, 2024
Semaglutide Shows Liver Benefits in Phase 3 MASH TrialNovember 25th, 2024
Join now to see all